In the clinical trial #NCT04485013, 200 patients with different types of cancer including head and neck squamous carcinomas, non-small cell lung cancer, colorectal cancer, and triple negative breast cancer are currently recruited for the treatment with the full human monoclonal antibody against HLA-G, named TTX-080. The gene discussed is HLA-G; the disease is triple-negative breast carcinoma.